Latest news with #JSPR
Business Insider
16-06-2025
- Business
- Business Insider
Jasper Therapeutics presents data from SPOTLIGHT Phase 1b/2a study
Jasper Therapeutics (JSPR) is presenting data from the 180mg cohort of the Company's SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with CIndU at the European Academy of Allergy and Clinical Immunology, EAACI, Annual Congress. Briquilimab administration resulted in deep disease control at 180mg, with 12 of 12 participants enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants achieving clinical response by week 2, and 7 of 12 participants maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort. Confident Investing Starts Here:
Yahoo
21-05-2025
- Business
- Yahoo
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential
We recently published an article titled . Jasper Therapeutics, Inc. (JSPR) was one of the stocks that was covered in that article. Wall Street analysts believe JSPR has a 914% upside potential over the next 12 months. A biotech scientist studying a microscope slide filled with hematopoietic stem cells. Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company that focuses on developing therapeutics targeting mast and hematopoietic stem cell-driven diseases. Its lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. JSPR focuses on the development and commercialization of therapeutic agents for patients with various mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. In terms of marketing and distribution, Jasper Therapeutics, Inc. (NASDAQ:JSPR) has established exclusive licensing agreements with Amgen and Stanford University for the development and commercialization of briquilimab. These collaborations are crucial for advancing the company's product candidates and expanding its research capabilities. The company stated on its website: "We have an exclusive license agreement with Amgen Inc. ('Amgen') for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories worldwide." It must be noted that Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported a net loss of $21.2 million for the first quarter of 2025, which was significantly higher than the previous year. This reflects increased operating expenses, primarily in research and development. The company's cash balance stands at $49.2 million as of March 31, 2025. Meanwhile, operating expenses were higher at $15.1 million, with research and development expenses rising from $10.3 million to $16.2 million, both on a year-on-year comparison. Ronald Martell, President and Chief Executive Officer of Jasper spoke on the company's performance: 'During the first quarter of 2025 we made great progress advancing briquilimab toward important data readouts later this year from all three of our clinical programs in mast cell diseases'. On May 15, 2025, Oppenheimer analyst Jay Olson issued an update on Jasper Therapeutics (JSPR, Financial), reaffirming the firm's 'Outperform' rating for the company but revising the price target. Analysts on Wall Street following the stock hold an optimistic view of the company, with a 'Strong Buy' rating and a consensus on the average price for the next twelve months estimated at $49.89, an upside of 914%. Overall, Jasper Therapeutics, Inc. (NASDAQ:JSPR) ranks 1st on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of JSPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JSPR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential
We recently published an article titled . Jasper Therapeutics, Inc. (JSPR) was one of the stocks that was covered in that article. Wall Street analysts believe JSPR has a 914% upside potential over the next 12 months. A biotech scientist studying a microscope slide filled with hematopoietic stem cells. Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company that focuses on developing therapeutics targeting mast and hematopoietic stem cell-driven diseases. Its lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. JSPR focuses on the development and commercialization of therapeutic agents for patients with various mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. In terms of marketing and distribution, Jasper Therapeutics, Inc. (NASDAQ:JSPR) has established exclusive licensing agreements with Amgen and Stanford University for the development and commercialization of briquilimab. These collaborations are crucial for advancing the company's product candidates and expanding its research capabilities. The company stated on its website: "We have an exclusive license agreement with Amgen Inc. ('Amgen') for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories worldwide." It must be noted that Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported a net loss of $21.2 million for the first quarter of 2025, which was significantly higher than the previous year. This reflects increased operating expenses, primarily in research and development. The company's cash balance stands at $49.2 million as of March 31, 2025. Meanwhile, operating expenses were higher at $15.1 million, with research and development expenses rising from $10.3 million to $16.2 million, both on a year-on-year comparison. Ronald Martell, President and Chief Executive Officer of Jasper spoke on the company's performance: 'During the first quarter of 2025 we made great progress advancing briquilimab toward important data readouts later this year from all three of our clinical programs in mast cell diseases'. On May 15, 2025, Oppenheimer analyst Jay Olson issued an update on Jasper Therapeutics (JSPR, Financial), reaffirming the firm's 'Outperform' rating for the company but revising the price target. Analysts on Wall Street following the stock hold an optimistic view of the company, with a 'Strong Buy' rating and a consensus on the average price for the next twelve months estimated at $49.89, an upside of 914%. Overall, Jasper Therapeutics, Inc. (NASDAQ:JSPR) ranks 1st on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of JSPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JSPR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
